Intramyocardial angiogenetic stem cells and epicardial erythropoietin save the acute ischemic heart

Disease Models & Mechanisms
C KlopschG Steinhoff

Abstract

Ischemic heart failure is the leading cause of mortality worldwide. An early boost of intracardiac regenerative key mechanisms and angiogenetic niche signaling in cardiac mesenchymal stem cells (MSCs) could improve myocardial infarction (MI) healing. Epicardial erythropoietin (EPO; 300 U kg-1) was compared with intraperitoneal and intramyocardial EPO treatments after acute MI in rats (n=156). Real-time PCR and confocal microscopy revealed that epicardial EPO treatment enhanced levels of intracardiac regenerative key indicators (SDF-1, CXCR4, CD34, Bcl-2, cyclin D1, Cdc2 and MMP2), induced transforming growth factor β (TGF-β)/WNT signaling in intramyocardial MSC niches through the direct activation of AKT and upregulation of upstream signals FOS and Fzd7, and augmented intracardiac mesenchymal proliferation 24 h after MI. Cardiac catheterization and tissue analysis showed superior cardiac functions, beneficial remodeling and increased capillary density 6 weeks after MI. Concomitant fluorescence-activated cell sorting, co-cultures with neonatal cardiomyocytes, angiogenesis assays, ELISA, western blotting and RAMAN spectroscopy demonstrated that EPO could promote cardiomyogenic differentiation that was specific of tissue origin an...Continue Reading

References

May 21, 2003·Circulation·Jeroen KoerselmanDiederick E Grobbee
Oct 3, 2003·The Journal of Clinical Investigation·Cyrus J ParsaWalter J Koch
Sep 30, 2004·Journal of Cardiovascular Pharmacology·Erik LipsicRegien G Schoemaker
May 24, 2006·Journal of Pharmacological Sciences·Daisuke NishiyaMinoru Yoshiyama
Sep 26, 2006·American Journal of Physiology. Heart and Circulatory Physiology·Fabrice PrunierRoger J Hajjar
Mar 24, 2007·Experimental Hematology·Kevin J ZwezdarykAline B Scandurro
Apr 7, 2007·The Journal of Biological Chemistry·Jing XuMingyao Liu
Aug 19, 2007·Current Neurovascular Research·Zhao Zhong ChongKenneth Maiese
Apr 9, 2008·Cell Research·Roel Nusse
Apr 10, 2008·Cardiovascular Research·Ian B CoplandJacques Galipeau
Jun 11, 2008·Cardiovascular Research·Hiroyuki KobayashiHisayoshi Fujiwara
Oct 2, 2008·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Stefan BrunnerWolfgang-Michael Franz
Feb 25, 2009·European Journal of Cardio-thoracic Surgery : Official Journal of the European Association for Cardio-thoracic Surgery·Deyan MihovReza Tavakoli
Apr 17, 2009·Nature·Vincent M ChristoffelsAndreas Kispert
Jul 28, 2009·Journal of Molecular and Cellular Cardiology·Marcin DobaczewskiNikolaos G Frangogiannis
Jun 19, 2010·Journal of Cardiovascular Translational Research·Ba-Khoi NguyenNicolas Noiseux
Aug 5, 2010·Cell Stem Cell·Ahmed MohyeldinAlfredo Quiñones-Hinojosa
Feb 11, 2011·Journal of Cellular and Molecular Medicine·Angelique A M van OorschotMarie-José Goumans
Feb 18, 2011·Disease Models & Mechanisms·Omonigho AisagbonhiAntonis K Hatzopoulos
Feb 25, 2011·Cardiovascular Research·Jun-Ming TangShi-You Chen
Mar 2, 2011·Cardiovascular Research·Signe CarlsonMark L Entman
Dec 6, 2011·Cell Stem Cell·James J H ChongRichard P Harvey
Feb 1, 2012·Journal of Cellular and Molecular Medicine·Alexander SchuhAlexander Sasse
Apr 28, 2012·Circulation Research·Tilanthi M JayawardenaVictor J Dzau

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR
enzyme-linked immunosorbant assay
reverse transcription PCR
fluorescence-activated cell sorting
ELISA
coronary artery bypass
Profiler

Software Mentioned

RAMAN
Axio Vision LE
Sigma Stat
ImageJ
ZEN
CAMO
[UNK] Profiler PCR Array Data Analysis Template
[UNK]
Unscrambler X
IOX

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Cardiac Regeneration

Cardiac regeneration enables the repair of irreversibly damaged heart tissue using cutting-edge science, including stem cell and cell-free therapy. Discover the latest research on cardiac regeneration here.

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Adult Stem Cells

Adult stem cells reside in unique niches that provide vital cues for their survival, self-renewal, and differentiation. They hold great promise for use in tissue repair and regeneration as a novel therapeutic strategies. Here is the latest research.